Effect of Thermosensitization with Parthenolide in Thermotherapy of Early Prostate Cancer Combined with Androgen Deprivation ; with an Emphasis on Histopathologic Findings
K. Koshiba, S. Hayashi, M. Aihara, Takefumi Sato, Yutaka Jujo, R. Suzuki, H. Mizoguchi, M. Hatashita, H. Nakajo, S. Shimura
求助PDF
{"title":"Effect of Thermosensitization with Parthenolide in Thermotherapy of Early Prostate Cancer Combined with Androgen Deprivation ; with an Emphasis on Histopathologic Findings","authors":"K. Koshiba, S. Hayashi, M. Aihara, Takefumi Sato, Yutaka Jujo, R. Suzuki, H. Mizoguchi, M. Hatashita, H. Nakajo, S. Shimura","doi":"10.3191/THERMALMED.29.47","DOIUrl":null,"url":null,"abstract":"Parthenolide(PTL),a nuclear factor-κB(NF-κB)inhibitor,has been known to have a significant thermo-enhancement efect.The purpose of this study is to report our clinical experiences of using PTL in perioperative period of transurethral microwave thermotherapy(TUMT)for the treatment of early prostate cancer and to compare the results with those of the patients who were treated in the similar manner without PTL administration.Al the patients who underwent TUMT for early prostate cancer were pretreated with androgen deprivation therapy(ADT)at least for 3 months to reduce volume of the prostate to render the TUMT more efective.PTL,daily oral dose of 0.5 mg,was administered during the perioperative period of TUMT. Forty-five patients with early prostate cancer,clinical stage T1c~T2cN0M0 were included in this study.Significant reduction in volume of the prostate(mean 34.6%)was noted after ADT for 3 months. Transurethral resection of the prostate in radical fashion was then performed at least 3 months after TUMT to wait for maturation of histopathologic changes of the prostate glands. Thorough histopathologic study of al the transurethral resection of the prostate(TURP)chips revealed no cancer cel in 41 of 45 patients.Among 4 patients who were found to have remnant cancer cels in TURP chips,1 was with non-viable cancer cels.Whereas,3 were with probably viable cancer Parthenolide in TUMT of prostate cancer・K.Koshiba et al. ― ― 47 Received 3 April,2013,Accepted 14 May,2013.Corresponding author;Tel,+81-3-3821-0502;Fax,+81-3-3821-1194; e-mail,ken604k@ma.kitanet.ne.jp doi:10.3191/thermalmed.29.47 ©2013 Japanese Society for Thermal Medicine cels,but apparently degraded in malignancy.These results were apparently superior to those of the 75 patients who were treated in similar manner before administration of PTL.Analyses were performed using Student’s t-test,chi-square test and Fisher’s exact test and ANOVA.","PeriodicalId":23299,"journal":{"name":"Thermal Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thermal Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3191/THERMALMED.29.47","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
引用
批量引用
Abstract
Parthenolide(PTL),a nuclear factor-κB(NF-κB)inhibitor,has been known to have a significant thermo-enhancement efect.The purpose of this study is to report our clinical experiences of using PTL in perioperative period of transurethral microwave thermotherapy(TUMT)for the treatment of early prostate cancer and to compare the results with those of the patients who were treated in the similar manner without PTL administration.Al the patients who underwent TUMT for early prostate cancer were pretreated with androgen deprivation therapy(ADT)at least for 3 months to reduce volume of the prostate to render the TUMT more efective.PTL,daily oral dose of 0.5 mg,was administered during the perioperative period of TUMT. Forty-five patients with early prostate cancer,clinical stage T1c~T2cN0M0 were included in this study.Significant reduction in volume of the prostate(mean 34.6%)was noted after ADT for 3 months. Transurethral resection of the prostate in radical fashion was then performed at least 3 months after TUMT to wait for maturation of histopathologic changes of the prostate glands. Thorough histopathologic study of al the transurethral resection of the prostate(TURP)chips revealed no cancer cel in 41 of 45 patients.Among 4 patients who were found to have remnant cancer cels in TURP chips,1 was with non-viable cancer cels.Whereas,3 were with probably viable cancer Parthenolide in TUMT of prostate cancer・K.Koshiba et al. ― ― 47 Received 3 April,2013,Accepted 14 May,2013.Corresponding author;Tel,+81-3-3821-0502;Fax,+81-3-3821-1194; e-mail,ken604k@ma.kitanet.ne.jp doi:10.3191/thermalmed.29.47 ©2013 Japanese Society for Thermal Medicine cels,but apparently degraded in malignancy.These results were apparently superior to those of the 75 patients who were treated in similar manner before administration of PTL.Analyses were performed using Student’s t-test,chi-square test and Fisher’s exact test and ANOVA.
Parthenolide热致敏在早期前列腺癌热疗联合雄激素剥夺中的作用强调组织病理学结果
Parthenolide(PTL)是一种核因子-κB(NF-κB)抑制剂,具有显著的热增强作用。本研究的目的是报告经尿道微波热疗(TUMT)围手术期应用PTL治疗早期前列腺癌的临床经验,并与不应用PTL的患者进行比较。所有接受早期前列腺癌TUMT治疗的患者都接受了至少3个月的雄激素剥夺治疗(ADT),以减少前列腺体积,使TUMT更有效。在TUMT围手术期给予PTL,每日口服剂量0.5 mg。本研究纳入45例临床分期为T1c~T2cN0M0的早期前列腺癌患者。ADT治疗3个月后,前列腺体积显著减少(平均34.6%)。经尿道前列腺根治性切除在TUMT后至少3个月进行,等待前列腺组织病理变化成熟。所有经尿道前列腺切除术(TURP)芯片的彻底组织病理学研究显示,45例患者中有41例未发现癌细胞。在TURP芯片中发现残留癌细胞的4例患者中,1例为不活的癌细胞。而在前列腺癌的TUMT中,有3例可能活癌的Parthenolide。Koshiba等。2013年4月3日收稿,2013年5月14日收稿。通讯作者,电话+ 81-3-3821-0502,传真+ 81-3-3821-1194;e-mail,ken604k@ma.kitanet.ne.jp doi:10.3191/thermalmed.29.47©2013 japan Society for Thermal Medicine cells,但在恶性肿瘤中明显退化。这些结果明显优于给予PTL前以类似方式治疗的75例患者。采用t检验、卡方检验、Fisher精确检验和方差分析进行分析。
本文章由计算机程序翻译,如有差异,请以英文原文为准。